THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

Priority Healthcare Corporation (Retired) (PHCC.X)

4/8/2005 Proxy Information

Mr. Salentine was a consultant from February 2001 to March 2002. Prior to that, he served as BWIs Executive Vice President and Chief Financial Officer until February 2001 when BWI was acquired by Cardinal. Mr. Salentine is currently a partner in Bindley Capital Partners, LLC.

Mr. McCormick was a consultant from February 2001 to March 2002. Prior to that, he served as the Executive Vice President, General Counsel and Secretary of BWI until February 2001 when BWI was acquired by Cardinal. Mr. McCormick is currently a partner in Bindley Capital Partners, LLC.

Mr. Myers was President of Priority Healthcare Corporation from July 1996 to March 2001, Chief Executive Officer from May 1997 to January 2002, Chief Operating Officer from July 1996 to May 1997, and a consultant to the health care industry from June 1995 through June 1996.

Mr. Bindley was the Chief Executive Officer of Priority Healthcare Corporation from July 1994 until May 1997 and President from May 1996 until July 1996.

3/31/2004 Proxy Information

Robert L. Myers was President from July 1996 to March 2001, Chief Executive Officer from May 1997 to January 2002 and Chief Operating Officer from July 1996 to May 1997.

William E. Bindley was Chief Executive Officer of Priority Healthcare Corporation from July 1994 until May 1997 and President from May 1996 until July 1996.

In 2001, the Company purchased substantially all of the assets of Lynnfield Compounding Center, Inc., Lynnfield Drug, Inc. and Freco, Inc., which had collectively been doing business as "Freedom Drug." Ms. Rondeau, the Executive Vice President--Specialty Pharmacy Sales and Marketing of the Company, was the founder and President of Freedom Drug, and joined the Company after the acquisition of Freedom Drug. In addition, Ms. Rondeau, and her husband, Mr. Denis A. Rondeau, were the sole shareholders of Freedom Drug. In 2003, the Company paid an aggregate amount of $7,000,000 to the Rondeaus as an earn-out payment related to the Freedom Drug acquisition.

4/14/2003 Proxy Information

No related party transactions or special relationships reported for this company. Director relationships marked "Outside Related" at this firm will most often be former executives of the company. Additional information regarding these relationships will be added during our regular updates.